Advancing RNA medicines through safer and more effective lipid nanoparticle delivery
‘Introducing ANNA: Turning Data into Better LNPs’
The ANNA model developed by Axelyf significantly advances lipid nanoparticle (LNP) modeling by improving predictions of mRNA delivery performance across diverse, unstandardized datasets.
A team of experts, driven by passion and precision
Founded in Hafnarfjörður, Iceland, the Axelyf team leverages decades of expertise in pharmaceutical R&D and its global network of partners and collaborators to specialize in optimizing delivery systems for promising small molecule drugs derived from natural sources.